Stimulating fermentation by the prolonged acceleration of gut transit protects against decompression sickness

Sébastien de Maistre¹, Nicolas Vallée², Sandrine Gaillard³, Claude Duchamp⁴ & Jean-Eric Blatteau¹

Massive bubble formation after diving can lead to decompression sickness (DCS). Gut fermentation at the time of a dive exacerbates DCS due to endogenous hydrogen production. We sought to investigate whether medium-term stimulation of fermentation as a result of polyethylene glycol (PEG)-induced acceleration of bowel transit before diving exacerbates DCS in rats. Seven days before an experimental dry dive, 60 rats were randomly divided in two groups: an experimental group treated with PEG (n = 30) and an untreated control group (n = 30). Exhaled hydrogen was measured before the dive. Following hyperbaric exposure, we assessed for signs of DCS. After anaesthetisation, arterial blood was drawn to assay inflammatory cytokines and markers of oxidative stress. PEG led to a significant increase in exhaled H₂ (35 ppm [10–73] compared with control 7 ppm [2–15]; p = 0.001). The probability of death was reduced in PEG-treated rats (PEG: 17% [95% CI 4–41] vs control: 50% [95% CI 26–74]; p = 0.034). In addition, inflammatory markers were reduced, and the antioxidant activity of glutathione peroxidase was significantly increased (529.2 U.l⁻¹ [485.4–569.0] versus 366.4 U.l⁻¹ [317.6–414.8]; p = 0.004). Thus, gut fermentation might have a positive effect on DCS. The antioxidant and neuroprotective properties of the fermentation by-products H₂ and butyrate may explain these results.

Given that the vast majority of decompression sickness (DCS) events occur although diving procedures have been followed by divers, we seek to verify whether intrinsic factors, such as gut fermentation (present before the dive), may be involved in DCS risk.

Diving is a risky activity that can lead to bubble formation in the bloodstream and tissues as a result of dissolved gas changing phases during an ascent. The level of venous gas emboli is associated with the risk of DCS¹. When too many bubbles are generated, signs and symptoms of DCS can occur². It is generally accepted that these bubbles form from pre-existing gaseous nuclei attached to vessel walls³. Bubbles cause cell damage⁴, prothrombotic phenomena, ischaemia and diapedesis⁵,⁶. The inflammation can spread systemically and may degenerate into a vicious cycle. Spinal cord and brain neurological damage underlie the most serious and common symptoms of DCS. Even after standard treatment with hyperbaric oxygen, 20–30% of victims suffer sequelae after neurological DCS⁷. Identifying and managing factors that might influence the risk of DCS is therefore an important issue.

It has been shown that the gut microbiota can affect the risk of DCS. In rats and humans diving with air, bacterial fermentation of undigested sugars, which is associated with an increase in hydrogen production at the time of diving, is accompanied by an increase in the incidence of DCS⁸,⁹. Similarly, it has been demonstrated that increased removal of diluent hydrogen by gut microbes can affect the risk of DCS, and both native and supplemental addition of hydrogen-metabolizing microbes help reduce DCS risk¹⁰–¹⁴. Given that hydrogen can diffuse across the gut wall, disperse throughout the body and contribute to the initial formation of inert gas bubbles from nuclei, i.e., the micro-bubbles that serve as the origin of desaturation events¹⁵, we also suggest a fraction of the

¹Service de Médecine Hyperbare et Expertise Plongée, HIA Sainte-Anne, BP600, Toulon, Cedex 9, France. ²Équipe Résidente de Recherche Subaquatique Opérationnelle, Institut de Recherche Biomédicale des Armées, BP 600, Toulon, Cedex 9, France. ³Biotech Services, Université de Toulon, CS 60584, Toulon, Cedex 9, France. ⁴LEHNA, UMR 5023-CNRS/UCBL, Université Claude Bernard Lyon 1, 43 Bd du 11 Novembre, 1918, Villeurbanne, Cedex, France. Correspondence and requests for materials should be addressed to S.d.M. (email: sebastien.de-maistre@intradef.gouv.fr)
H₂ generated by excessive fermentation in the gut could have a harmful effect during decompression by directly increasing the amount of inert gas. It has been widely demonstrated that bowel transit time affects the gut microbiota and fermentation. In both humans and animals, rapid bowel transit is associated with increased faecal mass and an increased concentration of H₂ in exhaled air, which reflects increased fermentation. In patients with short bowel syndrome, oro-caecal transit is accelerated, and fermentation capacity is increased. Stress is also accompanied by accelerated transit throughout the digestive tract. Bowel transit can also be accelerated in normal circumstances, e.g., as a result of aerobic physical exercise or following the consumption of unfermentable cellulose. Bowel transit may also be accelerated pharmacologically. High-molecular weight polyethylene glycol (PEG) is a long linear polymer of ethylene glycol monomers that binds water molecules through hydrogen bonds. PEG cannot be digested or fermented. When administered orally, PEG increases the volume of fluid present in the gut, explaining the solution’s underlying laxative activity. PEG increases bowel transit in both the small intestine and colon. In non-fasting mice inoculated with human faecal micro-organisms, long-term PEG administration increases transit, induces changes in the composition of the gut microbiota similar to those observed on a diet based on unfermentable cellulose, and increases fermentation capacity.

The aim of these experiments was to investigate whether medium-term stimulation of fermentation by accelerating bowel transit increases the risk of DCS. Before the dive, rats were fed PEG for a week to stimulate gut fermentation. We initially decided to assess the effect of PEG ingestion at the clinical level on rats more likely to report DCS, i.e., on heavier rats (H), following pathogenic decompression. Then, the impact of this treatment was assessed on selected rats less likely to report DCS (low-risk population or lighter rat: L), in which blood cell counts and biochemical analyses could be performed more accurately, i.e., without interference from the major clinical symptoms of DCS (such as death).

Results
Clinical study in the at-risk population. Population characteristic: Body weight/fluid taken in. On the day of pressurisation, no difference in body mass was noted between the 36 polyethylene (PEG) and control (CTRL) rats (PEGH vs CTRLH: n = 18/18, 409 g [403–421] versus 392 g [385–416]; p = 0.205). The volume of fluid taken in was not different between the two groups (PEG H vs CTRL H: 295 ml [270–340] vs 289 ml [256–327], p = 0.438).

Gut activity and fermentation activity: Stools/Caecum with Short-chain fatty acids/Hydrogen and carbon dioxide in exhaled air. The weight of stools collected over two days was significantly increased in the PEG group (PEGH vs CTraction: 14.3 g [12.8–16.3] vs 8.3 g [8.0–9.0], p = 0.0001). The same was true for the weight of water in stools (PEGH vs CTRLH: 3.7 g [2.6–8.6] vs 1.3 g [1.1–2.0], p = 0.0001) and their dry weight (PEGH vs CTRLH: 10.7 g [9.7–11.9] vs 7.0 g [6.2–7.2], p = 0.0001) (Fig. 1).

Caeicum weight was also significantly increased in the PEG group (PEGH vs CTraction: 11.5 g [10.6–13.2] vs 6.9 ml [6.3–8.0], p < 0.0001).

The proportion of butyrate in the caecal content was significantly increased in the PEG group (PEGH vs CTraction: 58.4% [53.0–65.4] vs 38.5% [32.4–40.7], p < 0.0001). The same finding applies to a lesser extent for propionate (PEGH vs CTraction: 16.5% [15.0–23.8] vs 16.0% [14.0–20.1], p = 0.052) and valerate (PEGH vs CTraction: 1.9% [1.5–2.8] vs 1.4% [1.2–1.7], p = 0.005). On the other hand, the proportion of acetate in the caecal content was significantly reduced in the PEG group (PEGH vs CTraction: 18.5% [10.0–23.4] vs 43.3% [40.8–47.4], p < 0.0001) (Fig. 1). A Spearman test detected a positive correlation between the proportion of butyrate in the caecal content and the weight of stools collected over two days (PEGH and CTraction Spearman correlation: r = 0.36, p = 0.0002).

Figure 1. Gut and fermentation activities in the at-risk population (Bu: butyrate, Pro: propionate, Ac: acetate, Va: valerate). *Denotes p < 0.05 between the groups.
One hour before pressurisation, significantly more \( \text{H}_2 \) was noted in the air exhaled by PEG \( \text{H} \) group rats (35 ppm [7–77] compared with 7 ppm [4–15], \( p = 0.047 \)) (Fig. 1). A Spearman test detected a positive correlation between \( \text{H}_2 \) in exhaled air and the weight of stools collected over two days (PEG \( \text{H} \) and CTRL \( \text{H} \): Spearman \( \text{H}_2/\text{stools} \): \( n = 36, \alpha = 0.05, p = 0.049 \)). In contrast, no significant difference was noted between the levels of \( \text{CO}_2 \) produced one hour before pressurisation by the PEG \( \text{H} \) and CTRL \( \text{H} \) groups (PEG \( \text{H} \) vs CTRL \( \text{H} \): 9.7 ml.min\(^{-1} \) [8.2–12.3] vs 8.8 ml.min\(^{-1} \) [7.6–12.6], \( p = 0.281 \)).

Blood cell counts. Before the dive, no differences in blood cells were noted between groups, confirming the lack of a treatment effect on the blood components (leukocytes, erythrocytes, and platelet count). In the PEG \( \text{H} \) and CTRL \( \text{H} \) groups, no significant differences in the haematocrit four hours before pressurisation (56.4% [52.6–59.8] compared with 54.0% [48.2–59.0]; \( p = 0.235 \)) or after (\( p = 0.812 \)) were observed between the two groups, suggesting a similar hydration status.

Clinical effect of the provocative dive in the at-risk population. The dive protocol resulted in DCS cases, especially in at-risk groups (PEG \( \text{H} \) and CTRL \( \text{H} \)), and the general symptoms included alterations in physical and behavioural performances, including decreased scores in all locomotor and neurological tests, among all groups included. Although no significant differences in the proportion of DCS were observed in the two at-risk groups, differences in severity were noted between the groups with notably increased mortality observed in untreated rats (Fig. 2). One convulsion was also noted in the CTRL \( \text{H} \) group. Significantly fewer deaths were noted in the PEG \( \text{H} \) group (17% [95% CI 4–41] versus CTRL \( \text{H} \) rats 50% [95% CI 26–74], \( p = 0.034 \)), and this group scored better in the righting reflex (2.0 [2.0–2.0] compared with 1.4 [0.3–2.0]; \( p = 0.014 \)). Animals in this group also tended to score better on the SFI test (2.0 [2.0–2.0] compared with 1.4 [0.0–2.0]; \( p = 0.097 \)).

In the at-risk population, the weight of stools collected over two days was significantly increased in those that survived compared with those that died (13.00 g [9.09–14.91] compared with 8.38 g [8.08–9.31]; \( p = 0.005 \)) regardless of PEG treatment. In addition, slightly more \( \text{H}_2 \) was noted in the air the survivor rats were exhaling one hour before pressurisation (22 ppm [6–59] compared with 7 ppm [3–16]; \( p = 0.077 \)). A Spearman test detected a positive correlation between the beam walk score and the weight of stools collected over two days (PEG \( \text{H} \) & CTRL \( \text{H} \), Spearman \( \text{beam}/\text{stools} \): \( n = 36, \alpha = 0.05, p = 0.009 \)).

Clinical and biological study in the low-risk population. Population characteristic: Body weight/Fluid taken in. On the day of pressurisation, there was no difference in weight between the 24 polyethylene and control rats (PEG \( \text{L} \) and CTRL \( \text{L} \): 368 g [361–371] versus 370 g [360–379]; \( p = 0.544 \)). The volume of fluid taken in was not different between groups (PEG \( \text{L} \) vs CTRL \( \text{L} \): 313 ml [289–359] vs 327 ml [243–364], \( p = 0.997 \)).

Gut activity and fermentation activity: Stools/Caecum with Short-chain fatty acids/Hydrogen and carbon dioxide in exhaled air. The weight of stools collected over two days was significantly increased in the PEG group (PEG \( \text{L} \) vs CTRL \( \text{L} \): 15.4 g [11.6–17.7] vs 8.7 g [6.6–11.3], \( p = 0.005 \)). The same was true of the weight of water (PEG \( \text{L} \) vs CTRL \( \text{L} \): 4.8 g [4.4–6.9] vs 2.1 g [1.8–2.5], \( p = 0.003 \)) and dry weight (PEG \( \text{L} \) vs CTRL \( \text{L} \): 9.4 g [7.1–11.2] vs 6.4 g [4.9–8.1], \( p = 0.035 \)) (Fig. 3).

Caecum weight was also significantly increased in the PEG group (PEG \( \text{L} \) and CTRL \( \text{L} \): 11.7 g [10.3–13.3] vs 7.1 g [4.6–7.8], \( p < 0.0001 \)). The proportion of butyrate in the caecal content was significantly increased in the PEG group (PEG \( \text{L} \) vs CTRL \( \text{L} \): 56.8% [39.1–65.5] vs 34.8% [30.1–35.8], \( p = 0.045 \)). The same finding applies for valerate (2.2% [1.9–2.4] vs 1.6% [1.2–1.9], \( p = 0.018 \)) but not for propionate (PEG \( \text{L} \) and CTRL \( \text{L} \): 25.1% [18.9–26.3] vs 18.6% [15.4–24.6], \( p = 0.207 \)). On the other hand, the proportion of acetate in the caecal content was significantly reduced in PEG...
Primary 9aec3fed97 97a284f39b8018-28510-x

Figure 3. Gut and fermentation activities in the low-risk population (Bu: butyrate, Pro: propionate, Ac: acetate, Va: valerate). *Denotes p < 0.05 between the groups.

Discussion

Although previous works seem to suggest that the risk of DCS increases according to hydrogen production (i.e., fermentation), our results highlight the fact that the risk decreases when fermentation is stimulated for one week.

PEG-induced fermentation. In rats fed a standard diet, we demonstrated that the ingestion of PEG for 7 days before a dive increases faecal production concomitant with enhanced hydrogen exhalation, and the latter of which reflects gut fermentation. Actually, this increase in faeces is accompanied by an increase in its dry and water content. Given that the haematocrit is unchanged, we can dismiss the possibility of dehydration. As a result of fermentation, the composition of faeces varies from one group to another with the treated rats having proportionally more butyrate, propionate or valerate and less acetate than the other groups. The increase in butyrate was...
at the expense of the acetate, as is described in fermentation processes occurring in the intestine. Finally, the increased faecal mass and hydrogen exhaled in air recorded in this study suggest rapid bowel transit and increased rate of fermentation, as suggested by various authors in both rats and humans.

Decompression sickness. DCS cases were generated using the same dive protocol as described in previous studies. Globally, DCS manifests as an alteration in physical and behavioural performances accompanied by a deterioration in biological constants.

In contrast to what was expected, this enhanced fermentation resulted in a significant reduction in the incidence of DCS based on the following mechanisms: (i) reduced mortality and sciatic nerve dysfunction in the at-risk population and (ii) reduced levels of circulating interleukins and blood parameters alterations (suggesting less premises for DCS) in the low-risk population. In control rats, in particular, we measured significant decreases in the platelet count mostly attributed to the interaction between bubbles and platelets in DCS as well as the leukocyte count. This finding is also consistent with the increase in pro-inflammatory IL-1 beta, suggesting that inflammation causes diapedesis.

Medium-term fermentation cuts down the risk of DCS. Taken together, these results suggest medium-term gut fermentation reduces the risk of DCS in rats. Thus, it seems that faster bowel transit could protect against DCS.

Fermentation effect on gas load and bubble-induced DCS. As stated above, increasing the water content of faeces potentially modified the hydration level and therefore increased the DCS risk, but this modification does not change the haematocrit or increase DCS symptoms in PEG-treated rats.

At first glance, the findings reported here might seem to contradict our previous results. In both studies, the aim was to stimulate gut fermentation and H₂ production.

In the course of hyperbaric exposure, the surplus load of inert gas in the form of H₂ generated by bacterial fermentation was assumed to induce a significant increase in bubble volume during decompression and promote DCS. In fact, this process did not occur in this study. It seems that insufficient H₂ was generated inside the body to exacerbate the risk of DCS in rats. In fact, the levels of H₂ measured in exhaled air one hour before these dives were significantly reduced compared with those reported previously (35 ppm [10–73] compared with 119 ppm [76–166]; p = 0.0003). In addition, although we previously stimulated H₂ production by administering a bolus...
dose of the fermentable mannitol four hours before the dive\(^9\), we only undertook a medium-term acceleration of bowel transit for a full 7 days before the dive and without a highly fermentable substance in this study. This finding suggests that protection from DCS by medium-term gut fermentation may require some time to benefit from the neuroprotective effects of endogenous H\(_2\) and butyrate, potentially explaining why no such effect was observed in the previous experiments\(^9\).

**Hydrogen and butyrate could protect from DCS.** Protective activity of H\(_2\): We observed a tendency towards a positive correlation between exhaled H\(_2\) and the activity of glutathione peroxidase, an enzyme with antioxidant properties. We suggest here that fermentation provides protection from DCS by the virtue of an antioxidative system. This hypothesis relies on the over-production of ROS (reactive oxygen species) and HSP (heat shock protein) in a dive\(^28\). It was also recently demonstrated in humans that successive deep dives have a negative effect on endothelial function and induce oxidative stress\(^29\). In a previous study, we demonstrated that endogenous H\(_2\) production as a result of bacterial fermentation could help prevent DCS\(^9\). Intraperitoneal administration of H\(_2\)-enriched normal saline over the 24-hour period before a high-risk dive can prevent DCS in rats\(^30\). H\(_2\) can act as an antioxidant by selectively reducing the hydroxyl radical (OH\(^-\)) and peroxynitrite anion (ONOO\(^-\)); however, H\(_2\) does not react with other biologically active reactive oxygen intermediates\(^31\). The same group demonstrated that inhaling H\(_2\) gas attenuates brain damage following focal ischaemia/reperfusion injury in rats by neutralizing the effects of oxidative stress. The mechanism of action underlying this phenomenon involves both anti-inflammatory and anti-apoptotic effects\(^32–34\). This result parallels results on cytokines and leukocytes presented in this study. H\(_2\) also limits broaching of the blood-brain barrier by reducing reactive oxygen intermediates and inhibiting the activity of matrix metalloproteinase-9\(^35\). Other studies have demonstrated that inhaled H\(_2\) can have a positive effect on medullary ischaemia-reperfusion lesions in rabbits\(^36\). Finally, endogenous H\(_2\) produced by fermentation after the ingestion of lactulose exerts neuroprotective effects with respect to ischaemia-reperfusion lesions in the rat brain\(^37\); the same mechanism could apply to DCS.

Butyrate: Gut gases do not exclusively include metabolites generated by bacterial fermentation of indigestible carbohydrates. Quantitative analyses of products of *in vitro* fermentation of lactulose have demonstrated that the main non-gaseous metabolites include acetic, lactic and butyric acids, which are all typically produced by *Clostridium* spp\(^38\). In addition, butyrate, a short-chain fatty acid that is increased in PEG rats in this study, is known for its neuroprotective activity. As an inhibitor of histone deacetylase, butyrate has antioxidant\(^39\), anti-inflammatory and anti-apoptotic effects\(^39–41\). The activation of microglial cells and macrophages/monocytes induced by definitive ablation of the middle cerebral artery, which damages white matter, is inhibited by butyrate\(^40\). Moreover, an association can be made with lower levels of variation in cytokines and leukocyte counts after the dive of the treated rats of this study. In these cases with the neurological form of DCS _SFI_ being reduced in PEG rats, it is of interest to note that hydroxybutyrate also significantly reduces brain damage and more globally cell death\(^39,42\).

**A biphasic effect.** Our findings point to a two-edged effect of gut fermentation on decompression. Despite being detrimental in the short term, i.e., at the time of diving, gut fermentation apart from dives might have a positive effect by preventing the occurrence of DCS and limiting its severity (Fig. 6). Thus, it might seem wise to reduce consumption of foodstuffs with high fermentation potential the day before a dive. In addition, any factor that might affect the gut microbiota and stimulate fermentation (prebiotic and probiotic products) could be tested to investigate its potential in protecting against DCS.

**Could it be applied in human dives?** To prevent DCS. An association between modification of the gut microbiota and increased fermentation was previously demonstrated in a number of cases, i.e., using prokinetic agents, such as cisapride in humans\(^15\) and bisacodyl in rats\(^17\). Regarding other molecules, an increase in the fermentation rate is expected from the inversely proportional relationship between bowel transit time and the amount of H\(_2\) in exhaled air\(^15–17\). This situation occurs with certain antiemetic agents, such as metoclopramide.

---

**Figure 6.** Summary of the effects of intestinal fermentation on the risk of decompression sickness.
and domperidone, which affect oro-caecal transit time. Regular physical exercise can also stimulate fermentation by accelerating oro-caecal transit and experiments on humanized mice (i.e., germ-free mice inoculated with human faecal microbiota) have demonstrated that a diet based on unfermentable cellulose increases gastrointestinal transit and induces changes in the gut microbiota similar to those observed after the administration of PEG. In turn, short-chain fatty acids, which result from gut fermentation, could also stimulate fermentation by increasing the rate of transit through the small intestine. H₂ produced in the colon could accelerate transit in this portion of the gut, especially the proximal colon.

To treat DCS. Due to lack of control of the gastrointestinal system by the central nervous system, many people with spinal cord damage suffer from impaired gut function with effects on bowel transit time. Specifically, the density of butyrate-producing bacteria is reduced in individuals with spinal cord damage compared with healthy subjects. Moreover, butyrate seems to have the ability to repair the blood-brain barrier by stimulating the expression of proteins found in tight junctions. By inhibiting histone deacetylase, butyrate also stimulates neurogenesis and could be implicated in the later stages of neurovascular recovery. Cell proliferation, migration and differentiation induced by the inhibition of histone deacetylase involve the brain-derived neurotrophic factor and its receptor tropomyosin receptor kinase B. Butyrate is a potent stimulant for vascular endothelial growth factor, which plays central roles in neurogenesis, angiogenesis and functional recovery after ischaemic stroke. Thus, replenishing butyrate-producing bacteria could also be effective in the management of neurological DCS.

Given the lack of knowledge, further experiments will be required to investigate the various factors that can accelerate bowel transit with the aim of preventing or treating DCS.

Conclusion
Our findings suggest that in contrast to what was expected medium-term stimulation of fermentation seems to reduce the risk of DCS in rats. Our findings point to a two-edged effect of gut fermentation on decompression. Although detrimental in the short term, i.e., at the time of diving, gut fermentation that occurs in the absence of diving might have a positive effect by preventing the occurrence of DCS and limiting its severity. H₂, which has antioxidant properties, and butyrate, a short-chain fatty acid, are both by-products of the fermentation of carbohydrate, and both could exhibit interesting neuroprotective activity. Stimulation of fermentation could also play a positive role when in the treatment of DCS.

Materials and Methods
The experimental design is presented in Fig. 7.
Study Population. All procedures involving experimental animals adhered to European Union rules (Directive 2010/63/EU) and French law (Decree 2013/118). The Ethics Committee of the Institut de Recherche Biomédicale des Armées approved this study (C2EA-SSA). Male Sprague-Dawley rats (Charles River Laboratory, France) were maintained in an accredited room at a temperature of 22 ± 1 °C with a day/night cycle of 12 hours each (light turned on at 7 a.m.). Before the experiments, the rats were fed a standard diet (12 mm granules from Global Diet 2018, Harlan, Italy) and water. Sixty rats were included in this study.

Drug and Treatment. The experimental group was treated with PEG for seven days before pressurisation. The treated rats were administered water supplemented with Fortrans® (IPSEN Pharma, France) (one sachet per litre, i.e., 64 g PEG 4000 per litre). The water that was administered to the control rats (CTRL) contained the same additives as Fortrans® without PEG. Throughout the treatment phase, the rats were housed in individual cages, and their food intake was controlled to maintain a constant weight (16 g granules a day).

Fluid consumed and stools produced. The amount of fluid consumed over 7 days was estimated by measuring the volume remaining in the rat’s bottle on the day of pressurisation. Consumption was normalised to each rat’s body weight.

Over the 48 hours before pressurisation, the weight of the faeces produced by each rat was measured. The litter was replaced two days before pressurisation. On the day of pressurisation, the litter was sieved to harvest all the stools passed over the last two days. These stools were then weighed, dried in an oven at 60 °C for 24 hours, and then weighed again to determine their dry weight.

Hydrogen and carbon dioxide in exhaled air. For all rats, the amount of H₂ measured in exhaled air provides a measurement of the rate of H₂ production resulting from the bacterial fermentation of carbohydrates in the gut (and hence diffusing throughout the body via the bloodstream). The amount of CO₂ in exhaled air depends on both the host’s metabolic activity and bacterial fermentation in the digestive tract (which diffuses across the gut wall).

For each measurement, each rat was placed in a clean, dry polystyrene cylinder (internal diameter 75 mm, length 200 mm, i.e., an internal volume of 883 ml). Both ends were hermetically sealed with plastic discs with holes in the middle, allowing air in at one end and the collection of gases at the other end. Air was circulated by a special aerator (Rena Air 200®, France) set to a constant flow rate of 225 ml.min⁻¹. Gases were mixed by an electric fan. The day-night cycle was respected throughout the experiment. The animals were captured with Seccagel (relative humidity: 40–60%) and soda lime (CO₂ absorber). Water vapour and CO₂ produced by the animals were circulated by a special aerator (Rena Air 200®, France) set to a constant flow rate of 225 ml.min⁻¹. Gases were mixed by an electric fan.

To measure H₂ and CO₂ in exhaled air, we considered that the breathing rate in rats is constant over time with a mean rate of 225 ml.min⁻¹. The literature provides a resting value of 27.27 ± 2.39 ml.min⁻¹.100 g⁻¹ (mean ± standard deviation) for Sprague-Dawley rats⁴⁹. The mean weight of the rats we studied was 389 ± 24 g (mean ± standard deviation). However, taking into account the stress induced by the measurement process, we used a breathing rate double that of the value in the literature for unstressed, resting rats.

For each measurement, each rat was placed in a clean, dry polystyrene cylinder (internal diameter 75 mm, length 200 mm, i.e., an internal volume of 883 ml). Both ends were hermetically sealed with plastic discs with holes in the middle, allowing air in at one end and the collection of gases at the other end. Air was circulated by a special aerator (Rena Air 200®, France) set to a constant flow rate of 225 ml.min⁻¹ that was controlled by the rise of a soap bubble in an inverted 100-ml test tube that was pierced at the bottom.

After 5 minutes (to allow time for the gases to mix inside the cylinder, taking account of the dead space, i.e., that not occupied by the animal), successive measurements of H₂ (ppm) and then CO₂ (percentage) in the air coming out of the cylinder were performed by means of a three-way tap. H₂ was measured using a mobile exhaled H₂ analyser (Gastrolyser®, Respur International, France), and CO₂ was measured using a mobile gas exchange test system (Cosmed® K4b², Italy). The results were recorded one hour before pressurisation. An illustration of the installation used to measure H₂ and CO₂ in exhaled air in rats can be found in a supplementary information file.

Hyperbaric procedure. Bubble formation and the incidence of DCS are highly dependent on body weight⁵⁰⁻⁵³. According to our previous study⁵⁴, this protocol using rats with a body weight greater than 350 g produces severe DCS with clear neurological involvement and death. All 60 rats, including 36 heavier rats (H) (weight of over 350 grams) and 24 lighter rats (L) (weight of less than 350 grams), were subjected to hyperbaric exposure followed by decompression to induce bubble formation and DCS. The aim was to obtain clear neurological signs and deaths in the Heavy rats (PEGH & CTRLH) and to induce non-fatal manifestations in Light rats (PEGL & CTRLL), which should not necessarily be detectable in a physical examination but should induce changes in blood tests.

All rats (PEGH & CTRLH) were subjected to air pressurisation at a rate of 10 kPa.min⁻¹ up to 100 kPa followed by a rate of 100 kPa.min⁻¹ up to 1000 kPa (90 msw), which was maintained for 45 minutes. At the end of the exposure period, the rats were decompressed to 200 kPa at a rate of 100 kPa.min⁻¹ with a 5-minute stop at 200 kPa, a 5-minute stop at 160 kPa, and a 10-minute stop at 130 kPa. Decompression between 200 kPa and the surface was conducted at a rate of 10 kPa.min⁻¹. The decompression rate was controlled automatically by a computer connected to an analogue/digital converter (NIUSB-6211®, National Instrument, USA) that was connected to a solenoid valve (Belino LR24A-SR®, Switzerland) and a pressure sensor (Pressure Transmitter 8314, Burket Fluid Control System, Germany). The software used to regulate the decompression rate was coded by our engineer using DasyLab (DasyLab®, National Instrument, USA).

Compressed air was generated using a diving compressor (Mini Verticus III, Bauer Comp, Germany) connected to a 100-litre buffer bottle at 3.10⁷ kPa. The oxygen analyser was based on a MicroFuel electrochemical cell (G18007 Teledyne Electronic Technologies/Analytical Instruments, USA). Water vapour and CO₂ produced by the animals were captured with Seccagel (relative humidity: 40–60%) and soda lime (CO₂ < 300 ppm), respectively. Gases were mixed by an electric fan. The day-night cycle was respected throughout the experiment. The
temperature inside the hyperbaric chamber was measured using a platinum resistance temperature probe (Pt 100, Eurotherm, France). All these variables were controlled by a dedicated computer.

Clinical observation. At the end of decompression, Heavy rats (PEG1 & CTRL1) were transferred into individual cages and observed at will for 30 minutes by trained observers who were unaware of the treatment. The following were considered as signs of DCS: motor deficit or difficulty moving around (including limping, failure to maintain balance, sideways gait, falling, and difficulty getting up after a fall) and death. Motor deficit was considered as anything below Level 4 on the Gale’s “Motor Score” scale. The time at which any sign was observed was recorded. Possible neurological damage was also assessed at higher resolution by means of a beam walk test that involved seven 110-cm long wooden planks of different widths (7.7–1.7 cm) raised 110 cm above the floor. The rats were first placed on the widest plank, and their ability to cross the plank without slipping was observed twice. This test was repeated with successively smaller planks, and the test was scored as the narrowest plank that the rat could cross, yielding a score of between 0 (dead) and 7.

The toe gap reflex test evaluates motor function and more specifically sciatic nerve function injury (SFI). The test is based visually on the toe gap where 2 represents a normal state, 1 a small gap and 0 a complete inability to spread the toes.

The righting reflex was elicited by holding the rat in one hand and turning it over on its back 7 or 8 cm above a covered table surface. The way the animal tried to regain its original position with its feet down was studied. To avoid injuring the rats when testing for righting, the animals with a motor score below 3 were tested for their ability to turn by dropping them from a height of 2 or 3 cm. Righting was scored as follows: 0, no attempt to right;

Blood cell counts. Counts were made on an automatic analyser (ABCvet®, SCIL, France) in samples taken four hours before pressurisation and then 30 minutes after removal from the hyperbaric chamber in the low-risk population. Red blood cells, haematocrit, leukocytes and platelets were counted in 20 µl samples taken from the tip of the tail and diluted in an equivalent volume of 2 mmol.l⁻¹ EDTA (Sigma, France). The second test values were corrected according to the hematocrit variation.

Samples taken after anaesthetisation. Thirty minutes after removal from the hyperbaric chamber, the rats were anaesthetised with an intraperitoneal injection of a mixture of 10 mg.kg⁻¹ xylazine (Rompum®, 2%, Bayer Pharma, Germany), 100 mg.kg⁻¹ ketamine (Imalgène®1000, Merial, France) and 1.65 mg.kg⁻¹ acepromazine (Calmivet®, Vet quo inol, France).

Inflammatory cytokines and markers of oxidative stress in the blood. Immediately after anaesthetisation, blood samples were obtained from the low-risk population by direct intra-aortic puncture for assays of IL-1β, IL-6, thiobarbituric acid reactive substances (TBARS) and glutathione peroxidase. Blood was collected in sterile 4-ml tubes containing lithium heparin (BD Vacutainer®, BD-Plymouth, UK). Within 30 minutes of sample collection, plasma was separated by simple centrifugation at 1200 g and 4 °C for 15 minutes. The supernatant was stored at −80 °C until testing. For the TBARS test, protein was removed from the plasma before storage: 100 µl of plasma was transferred into a 1.5-ml Eppendorf tube, and 200 µl iced 10% TCA was added. After 5 minutes of incubation, the tube was spun at 14.000 rpm for 5 minutes. This supernatant was also stored at −80 °C until testing.

Inflammatory cytokines and markers of oxidative stress were assayed using a Bioplex100 (Biorad Inc., CA, USA) and a series of kits: Rat IL-1β ELISA Kit, Rat IL-6 ELISA Kit (Sigma-Aldrich, MO, USA), QuantiChrom TBARS Assay Kit and EnzyChrom Glutathione Peroxidase Assay Kit (BioAssay Systems, CA, USA). Samples, standards and quality controls were all run in duplicate. All standards and quality controls were prepared as recommended by the supplier.

Short-chain fatty acids in the contents of the caecum. Immediately before sacrifice, the caecum was separated from the rest of the digestive tract after ligation. The caecum was weighed and then opened up using a scalpel. Part of its contents was placed in a 1.5-ml Eppendorf tube and frozen at −80 °C. Short-chain fatty acids (acetate, propionate, isobutyrate, butyrate, isovalerate, valerate) were assayed in the frozen sample by gas chromatography–mass spectrometry (GC-MS). The concentration of each short chain fatty acid was expressed as a percentage of the total concentration of short-chain fatty acids in the caecum.

Statistical analysis. Numerical data were expressed as median [interquartile interval] for quantitative variables and as a percentage [95% confidence interval] for binary variables. A contingency table was used for independence and association tests coupled with an exact Fisher or Chi-squared test. A Mann-Whitney test was used to analyse differences between unpaired groups, and a Wilcoxon test was used for comparisons within paired groups. Spearman’s test was used to investigate correlations. Differences were considered as significant if the p-value was less than 0.05. Statistical calculations were performed using XLSTAT-Pro® software (Addinsoft, Paris, France).

References
1. Nishi, R. Y., Brubakk, A. O. & Eftedal, O. S. Bubble detection in The Bennett and Elliot’s Physiology and Medicine of Diving edited by Brubakk, A. O. & Neuman, T. S. pp. 501–529 (WB Saunders, London, 2003).
2. Bert, P. La pression barométrique. [Barometric pressure] (Masson, 1878).
3. Blatteau, J. E., Sourraud, J. B., Gempp, E. & Boussuges, A. Gas nuclei, their origin, and their role in bubble formation. Aviat Space Environ Med 77(10), 1068–1076 (2006).

4. Vallee, N., Gaillard, S., Peinequin, A., Risso, J. J. & Blatteau, J. E. Evidence of cell damages caused by circulating bubbles: high level of free mitochondrial DNA in plasma of rats. J Appl Physiol 2015 115, 1526–1532 (2013).

5. Francis, T. J. & Mitchell, S. J. Pathophysiology of decompression sickness in Bennett and Elliott’s Physiology and Medicine of Diving, edited by Brubakk, A. O. & Neuman, T. S.. pp. 530–536 (WB Saunders, London, 2003).

6. Helps, C. C. & Gorman, D. F. Air embolism of the brain in rabbits pretreated with meclothemethane. Stroke 22, 351–354 (1991).

7. Blatteau, J. E. et al. Prognostic factors of spinal cord decompression sickness in recreational diving: retrospective and multicentric analysis of 279 cases. Neurocrit Care 15(1), 120–127 (2010).

8. de Maistre, S. et al. Gut fermentation seems to promote decompression sickness in humans. J Appl Physiol 1985 121, 973–979 (2016).

9. de Maistre, S. et al. Colonie Fermentation Promotes Decompression sickness in Rats. Sci Rep 6, 20379 (2016).

10. Kayar, S. R. & Fahlmans, A. Decompression sickness risk reduced by native intestinal flora in pigs after H2 dives. Undersea Hyperb Med 28(2), 89–97 (2001).

11. Kayar, S. R. et al. Decompression sickness risk in rats by microbial removal of dissolved gas. Am J Physiol 275(4 Pt 2), R677–R682 (1998).

12. Kayar, S. R. Biochemical Approach to Decompression in The future of diving: 100 years of Haldane and beyond, edited by Brubakk, A. & Lang, M.A., pp. 33–39 (Smithsonian Institution Scholarly Press, Washington, DC, 2009).

13. Kayar, S. R., Fahlmans, A., Lin, W. C. & Whitman, W. B. Increasing activity of H(2)-metabolizing microbes lowers decompression sickness risk in pigs during H(2) dives. J Appl Physiol 1985 91(6), 2713–2719 (2001).

14. Fahlmans, A., Tikuissis, P., Him, J. E., Weathersby, P. C. & Kayar, S. R. On the likelihood of decompression sickness during H(2) biochemical decompression in pigs. J Appl Physiol 1985 91, 2729–2739 (2001).

15. El Oufir, L. et al. Effect of drugs on oro-caecal transit time assessed by the lactulose/breath hydrogen method. Clin Physiol Funct Imaging 21(4), 292–297 (2001).

16. Lewis, S. J. & Heaton, K. W. Increasing butyrate concentration in the distal colon by accelerating intestinal transit. Gut 41(2), 245–251 (1997).

17. Bustos, D. et al. Effect of loperamide and bisacodyl on intestinal transit time, fecal weight and short chain fatty acid excretion in the rat. Acta Gastroenterol Latinoam 21(1), 3–9 (1991).

18. Briet, F. et al. Bacterial adaptation in patients with short bowel and colon in continuity. Gastroenterologia 109(5), 1446–1453 (1995).

19. Enck, P., Merlin, V., Eckenbrecht, J. & Wienbeck, M. Stress effects on gastrointestinal transit in the rat. Gut 30(4), 455–459 (1989).

20. Kashyap, P. C. et al. Complex interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice. Gastroenterology 144(5), 967–977 (2013).

21. Basit, A. W. et al. The effect of polyethylene glycol 400 on gastrointestinal transit: implications for the formulation of poorly-water soluble drugs. Pharm Res 18(8), 1146–1150 (2001).

22. Schulze, J. D. et al. Concentration-dependent effects of polyethylene glycol 400 on gastrointestinal transit and drug absorption. Pharm Res 20(12), 1984–1988 (2003).

23. Coremans, G., Vos, R., Margaritis, V., Ghooys, Y. & Janssens, J. Small doses of the unabsorbable substance polyethylene glycol 3350 accelerate oro-caecal transit, but slow gastric emptying in healthy subjects. Dig Liver Dis 37(2), 97–101 (2005).

24. Gremse, D. A., Hixon, J. & Crutchfield, A. Comparison of polyethylene glycol 3350 and lactulose for treatment of chronic constipation in children. Clin Pediatr (Phila) 41(4), 225–229 (2002).

25. Schweizer, L. S. & Krebs, S. J. In Oligosaccharides: Food Sources, Biological Roles and Health Implications Biochemistry research trends series 360p (Nova Science Publishers, Incorporated, 2013).

26. Cosnard, C. et al. Thirty-five Day Fluoxetine Treatment Limits Sensory-Motor Deficit and Biochemical Disorders in a Rat Model of Decompression Sickness. Front Physiol 8, 604 (2017).

27. Nossum, V., Hjelde, A. & Brubakk, A. O. Small amounts of venous gas embolism cause delayed impairment of endothelial function and increase polymorphonuclear neutrophil infiltration. Eur J Appl Physiol 86, 209–214 (2002).

28. Elfredal, J. et al. Acute and potentially persistent effects of scuba diving on the blood transcriptome of experienced divers. Physiol Genomics 45, 965–972 (2013).

29. Obad, A. et al. Successive deep dives impair endothelial function and enhance oxidative stress in man. Clin Physiol Funct Imaging 30(6), 432–438 (2010).

30. Ni, X. X. et al. Protective effect of hydrogen-rich saline on decompression sickness in rats. J Transl Med 8, 604–609 (2011).

31. Ohsawa, I. et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med 13, 688–694 (2007).

32. Liu, Y. et al. Hydrogen saline offers neuroprotection by reducing oxidative stress in a focal cerebral ischemia-reperfusion rat model. Med Gas Res 1, 15 (2011).

33. Ji, Q. et al. The effect of hydrogen-rich saline on the brain of rats with transient ischemia. J Surg Res 168, 695–701 (2011).

34. Wei, R., Zhang, R., Xie, Y., Shen, L. & Chen, F. Hydrogen Suppresses Hypoxia/Reoxygenation-Induced Cell Death in Hippocampal Neurons Through Reducing Oxidative Stress. Cell Physiol Biochem 36, 585–598 (2015).

35. Takeuchi, S. et al. Hydrogen improves neurological function through attenuation of blood-brain barrier disruption in spontaneously hypertensive stroke-prone rats. BMC Neurosci 16, 22 (2015).

36. Huang, Y. et al. Beneficial effects of hydrogen gas against spinal cord ischemia-reperfusion injury in rabbits. Brain Res 1378, 125–136 (2010).

37. Zhai, X. et al. Lactulose ameliorates cerebral ischemia-reperfusion injury in rats by inducing hydrogen by activating Nrf2 expression. Free Radic Biol Med 65, 731–741 (2013).

38. Sahota, S. S., Bramley, P. M. & Menzies, I. S. The fermentation of lactulose by colonic bacteria. J Gen Microbiol 128, 319–325 (1982).

39. Sun, J. et al. Neuroprotective Effect of Sodium Butyrate against Cerebral Ischemia/Reperfusion Injury in Mice. Biomed Res Int 2015, 959595 (2015).

40. Kim, H. J. & Chuang, D. M. HDAC inhibitors mitigate ischemia-induced oligodendrocyte damage: potential roles of oligodendrogenesis, VEGF, and anti-inflammation. Am J Transl Res 6, 206–223 (2014).

41. Sun, J. et al. Clostridium butyricum pretreatment attenuates cerebral ischemia/reperfusion injury in mice via anti-oxidation and anti-apoptosis. Neurosci Lett 613, 30–35 (2015).

42. Shen, Z. et al. Inhibition of G protein-coupled receptor 81 (GPR81) protects against ischemic brain injury. CNS Neurol Ther 21, 271–279 (2015).

43. Staniforth, D. H. Effect of drugs on oro-caecal transit time assessed by the lactulose/breath hydrogen method. Eur J Clin Pharmacol 33, 55–58 (1987).

44. Richardson, A., Delbridge, A. T., Brown, N. J., Rumsey, R. D. & Read, N. W. Short chain fatty acids in the terminal ileum accelerate stomach to caecum transit time in the rat. Gut 32, 266–269 (1991).

45. Jouet, P. et al. Effects of therapeutic doses of lactulose vs. polyethylene glycol on isotopic colonic transit. Aliment Pharmacol Ther 27, 988–993 (2008).
46. Jahng, J., Jung, I. S., Choi, E. J., Conklin, J. L. & Park, H. The effects of methane and hydrogen gases produced by enteric bacteria on ileal motility and colonic transit time. *Neurol. Gastroenterol. Motil.* 24, 185–190, e192 (2012).
47. Gungor, B., Adiguzel, E., Gursel, I., Yilmaz, B. & Gursel, M. Intestinal Microbiota in Patients with Spinal Cord Injury. *PLoS One* 11, e0145878 (2016).
48. Li, H. *et al.* Sodium butyrate exerts neuroprotective effects by restoring the blood-brain barrier in traumatic brain injury mice. *Brain Res* 1642, 70–78 (2016).
49. Strohl, K. P. *et al.* Ventilation and metabolism among rat strains. *J Appl Physiol* 82(1), 317–323 (1997).
50. Berghage, T. E., David, T. D. & Dyson, C. V. Species differences in decompression. *Undersea Biomed Res* 6(1), 1–13 (1979).
51. Montcalt-Smith, E. A., Fahlman, A. & Kayar, S. R. Pharmacological interventions to decompression sickness in rats: comparison of live agents. *Aviat Space Environ Med* 79(1), 7–13 (2008).
52. Lillo, R. S. *et al.* Using animal data to improve prediction of human decompression risk following air-saturation dives. *J Appl Physiol (1985)* 93, 216–226 (2002).
53. Fahlman, A. Allometric scaling of decompression sickness risk in terrestrial mammals; cardiac output explains risk of decompression sickness. *Sci Rep* 7, 40918 (2017).
54. Blatteau, J. E. *et al.* Protective effects of fluoxetine on decompression sickness in mice. *PLoS One* 7, e49069 (2012).
55. Gale, K., Kerasidis, H. & Wrathall, J. R. Spinal cord contusion in the rat: behavioral analysis of functional neurologic impairment. *Exp Neurol* 88(1), 123–134 (1985).
56. von Euler, M., Akesson, E., Samuelsson, E. B., Seiger, A. & Sundstrom, E. Motor performance score: a new algorithm for accurate behavioral testing of spinal cord injury in rats. *Exp Neurol* 137(2), 242–254 (1996).
57. Pockett, S. & Gavin, R. M. Acceleration of peripheral nerve regeneration after crush injury in rat. *Neurosci Lett* 59, 221–224 (1985).

**Acknowledgements**

We are very grateful to Myriam Dalous for her excellent technical assistance, and to Bruno Schmid, our Research & Development engineer for his valuable contribution. The research was supported by the “Délégation Générale pour l’Armement” (COSSA2015). It should be attributed to the “Institut de Recherches Biomédicales des Armées” laboratories (Toulon, France).

**Author Contributions**

Experiments designed by: S.d.M., N.V. and J.E.B. Experiments performed by: S.d.M., N.V. and J.E.B. Data analysed by: S.d.M. and J.E.B. Reagents/materials/analysis tools contributed by: S.d.M., N.V. and S.G. Author: S.d.M. and J.E.B.

**Additional Information**

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-28510-x.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018